Form 4: Ionis Pharmaceuticals EVP Eric Swayze Granted Stock Options
SEC Form 4
EVP Eric Swayze receives stock options, and a grant is made to his son, under Ionis Pharmaceuticals' equity incentive plan.
Summary
- Eric Swayze, EVP of Research at Ionis Pharmaceuticals, was granted 22,000 non-qualified stock options on January 2, 2025.
- These options have an exercise price of $34.69.
- Additionally, 163 non-qualified stock options were granted to Swayze's son on the same date.
- Both grants are part of the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- The options vest over a period of 3 years, with 25% vesting on January 2, 2026, and the remainder vesting in 36 equal monthly installments.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns management interests with shareholders.
Positives
- The grant of stock options to executive leadership and family members aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation strategy.
- The vesting schedule of 3 years with a 25% cliff at one year is a fairly standard vesting arrangement.
Stakeholder Impact
- Shareholders may view the stock option grants positively as they incentivize management to increase shareholder value.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of stock option grant to Eric Swayze and his son. |
| 01/02/2026 | 25% of the granted stock options will vest. |
| 01/01/2035 | Expiration date of the stock options. |
| 01/03/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.